National Institutes of Health, a Component of the US Dept. of Health & Human Services

Syed Kasmiri

Jeffrey Schlom

Eduardo Agustin Padlan

Rafia Mehdi Kashmiri, Legal Representative

The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.

Growing community of inventors

North Potomac, MD, United States of America

Syed Kasmiri